On-Demand CME Videos
Topical Therapies for Acne Management: Evolving Skin One Patient at a Time: Online CME Activity
About
To find out the correct answer, click "Start Activity."
When recommending clascoterone cream for your patient it is:
a. recommended for QD use
b. systemically absorbed in measurable quantities
c. normalizing follicular hyperkeratinzation
d. an androgen-receptor inhibitor
e. not safe for use in men
This activity is supported by an educational grant from Ortho Dermatologics was recorded at the 2022 Fall Clinical Dermatology Conference on October 20, 2022.
Availability
In order to ensure educational material is relevant, educational materials will expire after a certain time period. This course will be available for the following dates:
November 15, 2022
November 15, 2024
Learning Objectives
At the completion of this activity, participants should be better able to:
Summarize the role of topical therapies for the management of acne
Identify patients who would benefit from topical acne treatments
Describe strategies to talk to patients about topical therapies to help improve adherence and patient outcomes
Intended Audience
Faculty
Hilary Baldwin, MD
Director, Acne Treatment and Research Center
Rutgers Robert Wood Johnson Medical Center
New Brunswick, NJ
James Del Rosso, DO
Adjunct Clinical Professor, Dermatology
Touro University Nevada
Henderson, NV
Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of University of Nevada and CMEsquared. The University of Nevada is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation Statement
The University of Nevada designates this enduring activity for a maximum of 0.50 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosures & Disclaimers
CONFLICTS OF INTEREST/DISCLOSURES
In accordance with the ACCME Standards for Commercial Support, balance, independence, objectivity, and scientific rigor are ensured in all CME activities. This requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with any ineligible companies. In addition, the content of this material has been approved by an independent peer reviewer.
Disclosures are as follows:
Grant/Research Support: Aclaris, Amgen, Anaptys Bio, Arcutis, Athenex, Bausch (Ortho), Biorasi, Botanix, Brickell, Cara Therapeutics, Cassiopea, Dermavant, EPI Health, Galderma, Genentech, Incyte, Janssen, LEO, Lilly, Novan, Pfizer, Ralexar, Sanofi Genzyme Regeneron, Sol-Gel, SUN, Vyne
Consultant: Abbvie, Aclaris, Almirall, Amgen, Arcuits, Bausch (Ortho), Biofrontera, Biopharmx, Blue Creek, BMS, Cassiopea, Dermata, Dermavant, Encore, EPI Health, Evoummune, Ferndale, Galderma, Incyte, Jem Health, LEO, La Roche Posay, Lilly, MC2, Novan, Pfizer, Sanofi Genzyme Regeneron, Sente, Sol-Gel, Sonoma, SUN, UCB, Verrica, Vyne
Speakers’ Bureau or Honoraria: Abbvie, Aclaris, Almiral, Amgen, Bausch (Ortho), Biofrontera, Encore, EPI Health Ferndale, Galderma, Genentech, Jem Health, LEO, Lilly, Pfizer, Sanofi Genzyme Regeneron, SUN, UCB, Verrica, Vyne
The planners have disclosed that they have no relevant financial relationships with any Ineligible Company in the past 24 months.
The University of Nevada discloses that all relevant conflicts have been satisfactorily mitigated.